Search clinical trials for: FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg

Total 415 results

GlaxoSmithKline

Completed

A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323

Hypertension

India
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom
St. Olavs Hospital
Ullevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaborators

Active, not recruiting

Candesartan for Migraine Prevention: (CandMig-3)

Migraine

Norway, Estonia
AstraZeneca

Completed

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

Hypertension

Russian Federation, Latvia, Romania, Slovakia, Belgium, Malta
Bayer

Withdrawn

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Hypertension

Italy
AstraZeneca

Completed

ARIA (Atacand Renoprotection In NephropAthy Pt.) (PCR)

Non-diabetic Nephropathy With Hypertension

Korea, Republic of
AstraZeneca

Completed

Candesartan Effect in Second Stage Arterial Hypertension (CAESAR)

Stage II Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Hypertension

India
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions

Hypertension

India
GlaxoSmithKline

Completed

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Cardiovascular Disease

India
EMS

Withdrawn

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Essential Arterial Hypertension
HK inno.N Corporation

Completed

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets (REVERT-K)

Hypertension, Hyperlipidemia

Korea, Republic of
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
AstraZeneca

Completed

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Proteinuria

Canada
Huazhong University of Science and Technology

Unknown

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Hypertension

China
Takeda

Completed

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

Hypertension
Ullevaal University Hospital
Takeda; AstraZeneca; Southern-Eastern Norway Health Authorities RHF

Completed

Scandinavian Candesartan Acute Stroke Trial (SCAST)

Stroke

Norway
AstraZeneca
Takeda

Completed

Diabetic Retinopathy Candesartan Trials (DIRECT)

Type 1 Diabetes

Denmark, Australia
HK inno.N Corporation

Unknown

Bioequivalence Study of CJ-30059 (CCA)

Healthy Volunteers

Korea, Republic of
Takeda

Completed

Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」

Hypertension

Japan
AstraZeneca

Completed

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

Hypertension

United States, France, Italy, United Kingdom, Germany, Poland, Ukraine, Belgium, Puerto Rico, Denmark
AstraZeneca

Completed

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) (HIP)

Hypertension

France, Germany, Poland, Ukraine, Belgium, Italy
Boryung Pharmaceutical Co., Ltd
Pusan National University Hospital; Ulsan University Hospital; Daegu Catholic... and other collaborators

Completed

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Hypertension

Korea, Republic of
AstraZeneca

Completed

Atacand (Candesartan) Real Life Study (Real Life)

Hypertension

Sweden
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Hypertension
Norwegian University of Science and Technology
AstraZeneca

Completed

Prophylactic Treatment of Episodic Cluster Headache

Cluster Headache

Norway
Hospital Israelita Albert Einstein
Libbs Farmacêutica LTDA

Recruiting

Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (OPTION TREAT)

Hypertension

Brazil
AstraZeneca

Completed

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg

Hypertension

United Kingdom, Germany, Sweden, Estonia, Lithuania, Poland, Ukraine, Denmark, Netherlands, France, Former Serbia and Montenegro
Bayer

Completed

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Hypertension

Germany, United States, Canada, Poland, United Kingdom, Belgium
Pharmtechnology LLC
Altasciences Company, Inc.

Completed

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

Bioequivalence

Canada
Takeda

Completed

A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

Type 2 Diabetes Mellitus and Microalbuminuria

Japan
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Essential Hypertension

Korea, Republic of
University of Sydney
The George Institute for Global Health, India

Terminated

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (CLARITY 2)

COVID-19 | SARS-CoV2 Infection

India
HK inno.N Corporation

Unknown

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Essential Hypertension

Korea, Republic of
Shin Poong Pharmaceutical Co. Ltd.

Completed

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Mayo Clinic

Completed

Angiotensin-II Blockade in Mitral Regurgitation

Mitral Regurgitation

United States
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Essential Hypertension

Korea, Republic of
HanAll BioPharma Co., Ltd.

Unknown

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

Hypertension
AstraZeneca

Completed

Bioequivalence Study in Healthy Subjects

Hypertension

United Kingdom
Slovak Academy of Sciences

Unknown

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (ADIRAS)

Hypertension

Slovakia
AstraZeneca
Takeda

Completed

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France (SISTOLA)

Heart Failure | Cohort Study

France
Takeda

Completed

Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)

Hypertension

Japan
Takeda

Completed

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

Hypertension | Obesity

Germany
Kaiser Permanente
University of California, Davis

Withdrawn

Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C

Hepatitis C

United States
Takeda

Completed

Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"

Hypertension
Merck Sharp & Dohme LLC
Pfizer

Completed

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Hypertension | Diabetes Mellitus, Type 2
AstraZeneca
Scentryphar Clinical Research; Cori Analyticals; Clínica São Lucas, Hospital... and other collaborators

Completed

Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal

Healthy

Brazil
Takeda

Completed

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

Hypertension

Ukraine, Germany
Herlev Hospital

Unknown

Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease

Cardiovascular Diseases | Kidney Failure, Chronic

Denmark
AstraZeneca

Completed

Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

Primary Hypertension

Romania

3

Subscribe